Home Research Training Publications Media Contact


Neonatal Immunization with pneumococcal conjugate vaccine (PCV)

Funding comes and from Wellcome Trust and the study has been conducted from 2005-2009.
This study aimed to investigate the safety of giving this vaccine when given after birth or at 1 month of age. We also wanted to investigate the immunogenicity or how much protective antibody is elicited by the vaccine when given at 0-1-2 or 1-2-3 months compared to children who did not receive PCV. A total 318 children completed the study. All the children received another pneumococcal vaccine called Pneumovax at 9 months. Recruitment of follow-up of this study was completed in 2009 and laboratory work is continuing. Our data shows that early scheduling of PCV at 0-1-2 or 1-2-3 is safe and induces protective antibody responses to all PCV serotypes in the vaccine. The antibody responses after boosting with PPV at 9 months are maintained to 18 months. The study has been conducted in collaboration with
Telethon Institute of Child Health Research and School of Pediatrics and Child Health and the University of Western Australia.


Infection and Immunity



Dr William Pomat
Deputy Director - Science and Unit Head

This website contains public information about our work. If you wish to reproduce our material, acknowledge the Papua New Guinea Institute of Medical Research as your source and contact us where appropriate.